Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SVP, Business Development

SVP, Chief Marketing Officer

SVP, CFO & Treasurer

SVP & General Counsel

President and CEO

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unm...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-05	Premium	sold	Premium	Premium	Premium	SVP, Business Development
2024-03-05	Premium	sold	Premium	Premium	Premium	SVP, Chief Marketing Officer
2024-03-05	Premium	sold	Premium	Premium	Premium	SVP, CFO & Treasurer
2024-03-05	Premium	sold	Premium	Premium	Premium	SVP & General Counsel
2024-03-05	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-04	Premium	sold	Premium	Premium	Premium	SVP, Business Development
2024-03-04	Premium	sold	Premium	Premium	Premium	SVP, Chief Marketing Officer
2024-03-04	Premium	sold	Premium	Premium	Premium	SVP & General Counsel
2024-03-04	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-04	Premium	sold	Premium	Premium	Premium	SVP, CFO & Treasurer
2024-02-16	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-16	Premium	acquired	Premium	Premium	Premium	SVP, Business Development
2024-02-16	Premium	acquired	Premium	Premium	Premium	SVP, CFO & Treasurer
2024-02-16	Premium	acquired	Premium	Premium	Premium	SVP & General Counsel
2024-02-16	Premium	acquired	Premium	Premium	Premium	SVP, Chief Marketing Officer
2023-08-21	Premium	sold	Premium	Premium	Premium	SVP, Chief Marketing Officer
2023-08-10	Premium	sold	Premium	Premium	Premium	-
2023-07-28	Premium	sold	Premium	Premium	Premium	SVP, CFO & Treasurer
2023-06-15	Premium	sold	Premium	Premium	Premium	SVP, CFO & Treasurer
2023-06-13	Premium	sold	Premium	Premium	Premium	SVP & General Counsel
2023-06-08	Premium	acquired	Premium	Premium	Premium	-
2023-06-08	Premium	acquired	Premium	Premium	Premium	-
2023-06-08	Premium	acquired	Premium	Premium	Premium	-
2023-06-08	Premium	acquired	Premium	Premium	Premium	-
2023-06-08	Premium	acquired	Premium	Premium	Premium	-

VNDA - Vanda Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for VNDA